False Positive — Suspicion of Cancer Disproven by Tests

A false positive refers to a diagnostic or screening result that incorrectly indicates the presence of a disease in a person who is actually disease-free. This concept is fundamentally tied to test specificity—the capacity of a medical test to accurately identify those without the condition. When specificity is incomplete, harmless physiological variations can trigger false alarms.

In oncology, common causes of false positives include benign inflammation, post-surgical scarring, cysts, infection, or non-cancerous cellular hyperplasia. Because screening tools are intentionally designed to be highly sensitive to avoid missing early cancers, they inevitably capture benign irregularities that require follow-up testing to clarify.

Experiencing a false-positive result can cause significant emotional distress, worry, and temporary disruption to your daily life while you wait for definitive answers. It often leads to secondary evaluations, such as additional imaging, blood tests, or invasive biopsies. Knowing that false positives are a common, manageable part of modern screening protocols helps you maintain perspective and approach confirmatory steps calmly.

False positives relate to test specificity. When an initial scan or biomarker test (such as CA-125, PSA, or a stool test) is abnormal, clinicians resolve the uncertainty using diagnostic imaging with higher anatomical detail (such as targeted ultrasound or multiparametric MRI) or by obtaining a definitive tissue biopsy.

False positives occur frequently in cancer screening programmes. Common examples include recalled screening mammograms for benign breast calcifications or cysts, elevated PSA blood levels caused by benign prostatic hyperplasia or prostatitis, lung nodule detection on low-dose CT scans, and non-cancerous polyps identified during colorectal screening.

Once confirmatory diagnostics establish that an abnormal finding was a false positive, cancer-directed therapies such as chemotherapy, radiotherapy, or oncological surgery are avoided entirely. Patients can safely return to standard, age-appropriate routine screening schedules without unnecessary medical interventions, protecting them from overtreatment.